I agree, but I really don't care. If it gets hit and goes to $5, that's lousy, but I also know that no matter how the market interprets the comments, the data we have and are collecting are all that matter for the next 30 days. If those deaths are the patients injected with Leronlimab, we will fall back to where we were on March 1. If we have overwhelming positive data to ultimately obtain approval, $10 bucks is in the rear view mirror.